|1972||Itoham Foods Inc, Central Research Institute, established in the Tokyo office.|
|1987||American Peptide Company established in Silicon Valley, CA, U.S.A.|
|1990||Itoham Foods Inc, Central Research Institute, relocated to Moriya City, Ibaraki Pref., Japan.|
|1991||“Hemron,” an iron-rich food supplement that includes heme iron, marketed.|
|1992||Manufacturing license acquired for “Thrombin,” a drug substance.
c-GMP facility for pharmaceutical peptide production built.
|1994||ELCATONIN “ITO,” a drug substance, approved.|
|1995||“Liver-Hi,” a liver hydrolysate, marketed as a food supplement.|
|1996||“GLUCAGON FOR INJECTION ‘ITO’,” a glucagon formulation, approved.|
|1999||“ITORELIN,” a buserelin acetate formulation, approved.|
|2000||Health Science Division established in Itoham Foods Inc.|
|2002||c-GMP plant of American Peptide Company built in Vista, CA, U.S.A.
“MINIHEPA INJECTION 500,” a parnaparin sodium formulation, approved.
|2003||Ito Life Sciences, Inc. established.
“VETERINARY ITORELIN INJECTION,” a busererin acetate formulation, approved.
“L-Carnitine” and “L-Carnitine Fumarate” marketed.
|2004||“RESOLMIN INJECTION 1000,” a dalteparin sodium formulation, approved.|
|2008||All the shares of Ito Life Sciences, Inc. including American Peptide Company and Ito Life Sciences (Shanghai), transferred to Otsuka Chemical Co., Ltd.|
|2009||The company name changed to ILS Inc.|
|2011||“L-Carnitine L-Tartrate” marketed.|
|2014||“Hemron 2HiWS,” a concentrated and water-soluble heme iron product, marketed.|
|2015||All the shares of American Peptide Company transferred to Bachem Holding AG.
DESMOPRESSIN NASAL SPLAY 0.01% “ILS,” a desmopressin formulation, approved.
|2018||Peptide business transferred to Otsuka Chemical Co., Ltd.
All the shares of ILS Inc. transferred to a subsidiary of Goldman Sachs Japan CO., Ltd. and a subsidiary of ORIX Corporation.
|2019||The head office relocated to Kandasuda-cho, Chiyoda-ku, Tokyo for business expansion.
The former head office changed to Moriya Site.